{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
NCT04162834: Phase 4 Interventional Completed Kidney Cancer
(2019)
Source URL:
First approved in 1995
Source:
Papaverine Hydrochloride by American Regent, Inc.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. Papaverine is a vasodilating agent. Papaverine is used for the treating certain conditions that are accompanied by smooth muscle spasms (eg, blood vessel, urinary, gallbladder, or intestinal spasm). Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries. Papaverine is a potent, specific inhibitor of PDE10A. Papaverine for treatment of erectile dysfunction (ED) is excluded from coverage.
Status:
Possibly Marketed Outside US
First approved in 1990
Source:
NDA019882
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Betiatide (CAS 103725-47-9; aka S-benzoylmercapto¬acetyltriglycine or 2-[[2-[[2-[(2-benzoylsulfanylacetyl)¬amino]¬acetyl]¬amino]¬acetyl]¬amino] acetic acid) is the API in TechneScan MAG3™; a kit for the preparation of technetium Tc 99m mertiatide. It is used in the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstruction and calculi. Furthermore it is used in providing renal function, split function, renal angiograms and renogram curves for whole kidney and renal cortex. Betiatide is light sensitive and must be protected as such.
Status:
Possibly Marketed Outside US
Source:
NCT04677712: Phase 4 Interventional Completed Edematous Fibrosclerotic Panniculopathy (EFP)
(2020)
Source URL:
First approved in 1990
Source:
M017
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Conditions:
Squalane is an emollient used as cosmetic ingredient. It naturally occurs in small amounts in the lipid layers of skin, and along with its precursor squalene, prevents moisture loss while restoring skin’s suppleness and flexibility. It is soluble in all common cosmetic media, and can be used without limits in all types of formulations being non-toxic and a non-irritant. It is used in skin care products as an active or inactive ingredient and can be used in emulsion composition in vaccines and some drug compositions. Squalane is a hydrogenated squalene - a natural product first extracted from shark liver oil, and later isolated from olive and palm oils. In a pure state, it is a mobile, colorless, odorless and tasteless hydrocarbon oil with good physical and chemical stability. Up to date, anticancer, antioxidant, drug carrier, detoxifier, skin hydrating, and emollient activities of squalane have been reported both in animal models and in vitro environments.
Status:
Possibly Marketed Outside US
First approved in 1988
Source:
NADA140441
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Enrofloxacin was developed by Bayer for the treatment of broad spectrum of bacterial infections in animals (cats and dogs). The drug exerts its action by inhibiting DNA Topoisomerase II (Gyrase) and DNA Topoisomerase IV (Topo IV), two major bacterial topoisomerase. Enrofloxacin was shown to be metabolized to ciprofloxacin and may cross the blood brain barrier in the animals.
Status:
Possibly Marketed Outside US
Source:
ESIKA EXPRESSION ANTIPERSPIRANT ROLL-ON DEODORANT by Winthrop
Source URL:
First approved in 1982
Source:
21 CFR 350
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Hydroxycitronellal is a perfume ingredient with a medium strength floral scent, reminiscent of lily and sweet tropical melon. It is produced synthetically from naturally occurring scent chemical citronellal. It is on the CFR - Code of Federal Regulations Title 21 list of synthetic flavoring substances and adjuvants. Hydroxycitronellal is banned in the European Union because of its toxic properties. Hydroxycitronellal is an allergen. Hydroxycitronellal has being shown to consistently modulate CCR5, CCL27, CCL2 and CCR7 in immature dendritic cells. Hydroxycitronellal is a TRPM8 agonist.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
BI-847325 is a novel, ATP-competitive, orally available inhibitor of Aurora kinases and
MEK. In in vitro studies, BI-847325 inhibited the activity of Xenopus laevis Aurora Kinase
B with an IC50 of 3 nM; with IC50 values for human Aurora kinase A and Aurora kinase C
being 25 and 15 nM, respectively. BI-847325 also inhibited human MEK1 and MEK2 with
respective IC50 values of 25 and 4 nM. BI-847325 had been in phase I clinical trials by Boehringer Ingelheim for the treatment of solid tumours. However, there is no development reported for this study.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Alprenolol is a beta adrenoreceptor blocking agent and 5HT1A antagonist, developed by AstraZeneca and now available as generic drug. It is used for treatment of hypertension, angina pectoris due to coronary atherosclerosis and acute myocardial infarction.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Chlormidazole was the first azole introduced the treatment of topical mycosis. It demonstrated inhibitory activity against many fungi and some gram-positive cocci. It is used for the treatment of fungal and bacterial infections of nails and skin, including interdigital and periungual mycoses. Possible side effects are: local skin irritation, burning, itching.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Acemetacin is a non-steroidal anti-inflammatory drug used for the treatment of osteoarthritis, rheumatoid arthritis, lower back pain, and relieving post-operative pain. It is manufactured by Merck KGaA under the tradename Emflex and is available in the UK as a prescription-only drug. Other brand names for acemetacin include Rheutrop (Austria), Acemetadoc, Acephlogont, Azeat, Rantudil (Germany, Hungary, Mexico, Portugal, Turkey), Gamespir (Greece), Oldan, Reudol (Spain), Tilur (Switzerland), Ost-map (Egypt). Acemetacin is a glycolic acid ester of indomethacin. The pharmacological activity resulting from acemetacin administration in man is derived from the presence of both acemetacin and indomethacin. The precise pharmacological mode of action of acemetacin is not known. However, unlike other NSAIDs, acemetacin is only a relatively weak inhibitor of prostaglandin synthetase. Prostaglandins are known to have an antisecretory and cytoprotective effect on the gastric mucosa. Acemetacin shows activity in many of the established in vitro tests of anti-inflammatory activity including inhibition of the release of a number of mediators of inflammation. Acemetacin is well absorbed after oral administration. Its major metabolite is indomethacin, which, after repeated administration is present at levels in excess of those of acemetacin. Acemetacin is bound to plasma protein to a slightly lesser extent than indomethacin and has a relatively short plasma elimination half-life. It is eliminated by both hepatic and renal mechanisms. The pharmacokinetics appear to be linear at recommended therapeutic doses, unaffected by moderate renal or hepatic impairment, and unchanged in the elderly.
Status:
Possibly Marketed Outside US
Source:
Gramplus by Institut de Recherches Chimiques et Biologiques Appliquees
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Clofoctol [2-(2,4-dichlorobenzyl)-4-(tetramethyl-1,1,3,3-butyl)phenol] is a synthetic antibacterial agent with bactericidal activity on various Gram-positive (especially S. pyogenes and S. pneumoniae, but also Corynebacterium spp. and Propionibacterium acnes) and some Gram-negative bacteria (including Haemophilus influenzae, Bordetella spp., Neisseria meningitides, and Neisseria gonorrhea). A peculiar property of clofoctol is the rapidity of the antimicrobial effect, similar to that of antiseptic compounds, which makes the development of resistance less likely. Following rectal administration of clofoctol, absorption is rapid and nearly complete (about 98%), with a good penetration in the lung tissue. Clofoctol is primarily metabolized by hepatic glucuronidation and excreted through the biliary system; renal elimination is negligible. Clofoctol compound has been used mainly in France (under the trade name Octoplus ) and Italy (as Gramplus) for the treatment of mild upper respiratory tract infections, especially in pediatric patients